As major study groups have yet to mandate the measurement of CD9 [32, 33], we propose its integration into the diagnostic immunophenotyping panel as a ready-to-use prognostic marker to inform risk stratification and management of childhood ALL. The gene discussed is CD9; the disease is acute lymphoblastic leukemia.